drugset / Trial / NCT04491084
FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy. This study is testing the safety and effectiveness of this treatment approach as compared to standard treatment options.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2022-08-18
- Completion
- 2022-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CDX-1140 | Monoclonal antibody | — | — |
| Subject | CDX-301 | Protein / enzyme biologic | — | — |